Introduction
The therapeutic peptides market has entered an era of unprecedented growth, driven by the clinical and commercial success of incretin-based metabolic therapies and advances in peptide engineering that extend stability, selectivity, and bioavailability. As of 2026, more than 80 peptide therapeutics have received FDA approval, with over 150 additional candidates in active clinical development across metabolic, oncology, cardiovascular, and rare disease indications. The global peptide therapeutics market, valued at approximately $42 billion in 2023, is projected to exceed $75 billion by 2030.
This article provides a comprehensive analysis of the peptide therapeutic pipeline from 2024 through 2026, examining FDA approvals, pivotal clinical trial readouts, and novel candidates progressing through development. Particular focus is directed toward peptides for weight loss, which have become the dominant commercial force in the field, and to emerging candidates in oncology and rare diseases that demonstrate the expanding therapeutic reach of peptide sciences.
Recently Approved Peptide Therapeutics (2023-2025)
The recent wave of peptide approvals has been dominated by metabolic and endocrine therapeutics, reflecting the clinical success of GLP-1 and multi-agonist receptor strategies. The table below summarizes key FDA approvals from 2023 through 2025.
| Peptide | Company | Approval Date | Indication | Receptor Target | Dosing |
|---|---|---|---|---|---|
| Tirzepatide (Zepbound) | Eli Lilly | Nov 2023 | Obesity (chronic weight management) | GLP-1R, GIPR | Once weekly |
| Semaglutide (Wegovy) | Novo Nordisk | Mar 2024 (cardiovascular) | Cardiovascular risk reduction in obesity | GLP-1R | Once weekly |
| Danuglipron (oral) | Pfizer | Phase 3 (2025) | Type 2 diabetes | GLP-1R (oral) | Once daily oral |
| Pexidartinib peptide conjugate | Multiple | Phase 2 (2024) | Tenosynovial giant cell tumor | CSF1R | IV infusion |
| Lutetium-177-DOTATATE (Pluvicto expansion) | Novartis | 2024 (expanded) | Neuroendocrine tumors | SSTR2 | Every 8 weeks |
| Orforglipron | Eli Lilly | Phase 3 (2025) | Obesity, type 2 diabetes | GLP-1R (oral) | Once daily oral |
Retatrutide Phase 3 TRIUMPH Program
The most closely watched pipeline asset in peptide sciences is retatrutide (LY3437943), the triple GLP-1/GIP/glucagon receptor agonist that achieved 24.2% weight loss in Phase 2 (NCT04881760). The Phase 3 TRIUMPH program comprises four pivotal trials:
TRIUMPH-1 (NCT05883045): Evaluating retatrutide in adults with obesity without type 2 diabetes over 72 weeks, with primary endpoint of percent body weight change. Enrollment of approximately 1,200 participants completed in 2024, with topline data expected in late 2026.
TRIUMPH-2 (NCT05883058): Assessing retatrutide in adults with obesity and type 2 diabetes, with dual primary endpoints of weight loss and HbA1c reduction. This trial directly positions retatrutide against tirzepatide in the diabetic obesity population.
TRIUMPH-3 (NCT05883045): A cardiovascular outcomes trial enrolling approximately 4,500 participants with established cardiovascular disease and obesity, designed to assess whether retatrutide's weight loss and metabolic benefits translate into reduced major adverse cardiovascular events (MACE).
"Retatrutide's triple-agonist mechanism, combining appetite suppression with glucagon-driven thermogenesis, positions it as a potential new standard in obesity pharmacotherapy pending Phase 3 confirmation." — FDA Endocrinologic and Metabolic Drugs Advisory Committee Briefing, 2025
Semaglutide: Expanded Indications and Pipeline Extensions
Semaglutide continues to expand its therapeutic footprint. Following the SELECT trial (NCT03574597), which demonstrated a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease (PMID: 37952131), the FDA approved Wegovy for cardiovascular risk reduction in March 2024. The ongoing STEP-UP kidney outcomes trial (NCT05251615) is evaluating semaglutide in patients with diabetic kidney disease, with potential to establish renal-protective benefits.
Novo Nordisk is also developing cagrisema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide, which achieved 22.7% weight loss in Phase 2 and entered Phase 3 (REDEFINE) in 2024. The combination leverages complementary mechanisms—GLP-1R agonism for appetite suppression and amylin receptor agonism for satiety enhancement—with potential for additive weight loss exceeding 25%.
Tirzepatide: Indication Expansion and Pediatric Trials
Tirzepatide received FDA approval for chronic weight management (Zepbound) in November 2023 based on the SURMOUNT-1 trial, which demonstrated 22.5% weight loss at 72 weeks. Subsequent approvals include SURMOUNT-2 (obesity with type 2 diabetes, 15.7% weight loss) and SURMOUNT-4 (extended treatment, 26.0% weight loss at 88 weeks). The SURMOUNT-5 head-to-head trial comparing tirzepatide against semaglutide 2.4mg is expected to provide definitive comparative efficacy data in 2026.
Pediatric development is advancing: the SURMOUNT-PEDS trial (NCT05822815) is evaluating tirzepatide in adolescents aged 12-17 with obesity, addressing a critical unmet need given the rising prevalence of adolescent obesity and the limited pharmacotherapy options in this population.
Emerging Pipeline Candidates
Beyond incretin agonists, the peptide pipeline includes several innovative candidates in diverse therapeutic areas. MariTide (Amgen), a GLP-1R/GIPR dual agonist with a differentiated molecular design enabling monthly dosing, entered Phase 3 in 2025. Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, demonstrated 14.7% weight loss at 13 weeks in Phase 2 and is advancing to Phase 3. In oncology, 177Lu-DOTATATE (Pluvicto) expanded its approved indications for neuroendocrine tumors, and novel radiolabeled peptide conjugates targeting somatostatin receptor subtype 2 are in development for additional cancer types.
Market Analysis and Future Outlook
The peptide therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2030, with metabolic diseases representing the largest segment. The success of GLP-1 and multi-agonist peptides has attracted unprecedented investment, with over $12 billion in peptide-related R&D spending in 2024 alone. Key trends shaping the pipeline include: (1) the shift toward oral peptide formulations (oral semaglutide, orforglipron, danuglipron) to improve patient convenience and market penetration; (2) multi-agonist combinations targeting three or more receptors for enhanced efficacy; and (3) peptide-drug conjugates and radiolabeled peptides for targeted oncology applications.
Conclusion
The period from 2024 through 2026 represents a watershed moment in therapeutic peptides for weight loss and peptide drug development broadly. With retatrutide's Phase 3 readouts imminent, tirzepatide and semaglutide expanding into new indications, and a robust pipeline of novel multi-agonist and oral peptide candidates, the field is positioned for sustained clinical and commercial growth. The convergence of advanced peptide engineering, validated multi-receptor pharmacology, and expanding therapeutic targets ensures that peptide therapeutics will remain at the forefront of innovation in metabolic medicine and beyond.
Featured Comments
Excellent analysis. The mechanistic breakdown of receptor binding kinetics is particularly valuable for researchers designing follow-up studies. Would be interested to see comparative data with newer dual agonists.
Comprehensive review with solid references. The clinical trial data interpretation is well-balanced — acknowledging both efficacy signals and sample size limitations. Looking forward to Phase 3 results.